Eric Kaneps
Vice-President of Sales & Marketing

About

Eric Kaneps serves as the Vice-President of Sales & Marketing at LTS Nasal and Sterile Drug Products and has been in this role since 2018. Mr Kaneps has over 25 years of experience in sales, business development and account management in the pharmaceutical industry. Mr Kaneps worked at DPT Laboratories as the Director of Business Development from 2001 to 2016.

In this role, he transitioned the OTC/Consumer Health-based business towards pharmaceutical-based nasal and sterile products, which became the foundation for Renaissance Lakewood (now LTS Nasal and Sterile Drug Products). In between his roles at the Lakewood site, he was Senior Vice-President of Business Development for Pharma-Tech Industries, a CMO that specialises in prescription and OTC ingestible and topical powder products. Mr Kaneps holds a BSBA in International Business & Economics from The Ohio State University, US.

Contributions

NASAL

REFRAMING THE ROLE OF NASAL SPRAYS IN AN INCREASINGLY PATIENT-CENTRIC DRUG DELIVERY LANDSCAPE

Eric Kaneps looks at the reality of nasal drug delivery for liquid formulations and considers how advances not only open new opportunities but can also be seen in the context of a groundswell of momentum around non-invasive, patient-centric delivery. Mr Kaneps reflects on how this shift in dynamics, coupled with a shift in mindset, is opening the door for pharmaceutical companies to expand their drug delivery options and fully optimise the development pathway for their molecule.

More contributions

EXPERT VIEW

MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING

Eric Kaneps discusses key emerging drug delivery trends poised to help the pharmaceutical industry meet the growing demand for patient-centric solutions, with a particular focus on nasal drug delivery, as the nasal spray repositioning of existing drugs offers a range of benefits, including rapid onset of action, improved bioavailability and ease of administration for patients.

EXPERT VIEW

THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION

Eric Kaneps discusses the benefits of nasal drug delivery compared with other administration routes – and the challenges in R&D and clinical manufacturing.